CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics could soar on the back of significant pipeline progress next year. Vertex's slow and steady approach to diversifying its lineup should eventually pay off.

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

CRISPR Therapeutics' approved medicine is making slow progress, but it has an exciting pipeline. Iovance Biotherapeutics is generating decent revenue, but it faces significant obstacles.

Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promising early efficacy, with huge addressable markets and the potential to disrupt standard-of-care regimens.

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.

It may be the spawn of a company that faded into irrelevancy, but GE Vernova is thriving as a standalone outfit. Most investors may not appreciate just how long it takes CRISPR Therapeutics to complete a dosing regimen and start collecting revenue.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.

Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also could deliver a win for investors.

Subscribers to  Chart of the Week  received this commentary on Sunday, November 16.

Bedell Frazier Investment Counselling LLC trimmed its stake in shares of CRISPR Therapeutics AG (NASDAQ: CRSP) by 48.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,646 shares of the company's stock after selling 7,118 shares during the period. Bedell Frazier

CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) has been given an average rating of "Hold" by the twenty-one research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and eleven have issued a buy recommendation on the company.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics AG remains a pioneering gene editing company, with Casgevy's slow commercial ramp and robust pipeline driving long-term potential. Despite Casgevy's $2.2M list price and broad approvals, revenue growth is gradual due to complex treatment logistics and patient adoption hurdles. CRSP's pipeline includes promising in-vivo cardiovascular, CAR-T oncology/autoimmune, and diabetes programs, with key updates expected in 2025.

Ark Investment sold 395,617 shares worth about $25 million. It represents a minor change in its 13F assets under management (AUM).